-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
TERAVOLT: Increased Risk of Morbidity for Patients with Lung Cancer and COVID-19 Drives Research Collaboration
By Joy Curzio Since the start of the COVID-19, it has been established that patients with cancer are more severely impacted by the virus than healthy individuals or than those with other conditions. One study noted a mortality rate of 28% for patients with cancer and COVID, with the risk of death increased for…
-
-
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
The referenced media source is missing and needs to be re-embedded.
-
Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations to Clinical Practice
By Kara Nyberg, PhD Posted: June 24, 2020 Over the past decade, lung cancer has emerged as a shining example of how precision medicine can dramatically improve patient outcomes. Up to 85% of patients with lung cancer harbor potentially actionable driver mutations, and matching targeted therapy to druggable alterations in the first-line setting prolongs survival…
-
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
By Kara Nyberg, PhD Posted: June 24, 2020 New findings from the TRACERx lung study underscore the value of using circulating tumor DNA (ctDNA) to predict NSCLC relapse postsurgery based on the detection of minimal residual disease (MRD). Moreover, the results appear sufficiently robust to begin to support use of ctDNA as a biomarker for…
-
Evolution of Research Using Patient-Reported Outcomes in Lung Cancer: A Q&A With Dr. Benjamin Movsas
Posted: June 24, 2020 The IASLC Lung Cancer News spoke with Benjamin Movsas, MD, regarding the evolution of patient-reported outcomes (PROs) for lung cancer. Dr. Movsas is the co-chair of the Patient-Centered Outcomes Research Committee for the NRG Oncology Cooperative Group, chair of the radiation oncology department at the Henry Ford Cancer Institute in Michigan,…
-
Sublobar Resections for Early Lung Cancer
By Tetsuya Mitsudomi, MD Posted: April 16, 2020 The general principle of surgery for cancer of any organ is to remove the entire tumor with adequate margins of normal tissue along with regional lymph nodes that may have the potential for metastatic spread, even if preoperative imaging studies do not indicate any signs of metastases.…
-
TTFields in Unresectable MPM: STELLAR Results in Practice
By Giovanni Luca Ceresoli, MD Posted: June 24, 2020 Dr. Giovanni Luca Ceresoli Tumor-treating fields (TTFields) are a noninvasive, regional treatment based on the delivery of low-intensity alternating electric fields by transducer arrays applied to the patient’s skin surrounding the tumor.1 TTFields extend survival in glioblastoma and are U.S. Food and Drug Administration (FDA)…
-
On the Backs of Specialists: LDCT Screening Has Heightened the Importance of Recent Improvements in Surgical and Radiation Techniques
By Brendon Stiles, MD, and Drew Moghanaki, MD, MPH Posted: June 24, 2020 Annual low-dose computed tomography (LDCT) detects more early-stage lung cancers and saves lives by preventing death in people who develop lung cancer. The recent report on the long-term follow-up of patients in the National Lung Screening Trial (NLST) makes a powerful argument…
-
‘Never Too Late’: Tobacco Cessation Programs Benefit Patients With Cancer
By Leah Lawrence Posted: June 24, 2020 In late February 2020, the U.S. Food and Drug Administration (FDA), American Association for Cancer Research (AACR), and the IASLC held its FDA/CDER-AACR-IASLC Workshop to address the criticality of tobacco use assessment in oncology therapeutic trials. During this workshop, several speakers discussed the importance of smoking cessation, especially…
View ILCN Archives
Provider Resources
Popular Articles